Clinical trials recruiting for Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Fewer than 3 recruiting trials found.
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| BGB-B2033 | 1 |
| Bevacizumab | 1 |
| Tislelizumab | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Arizona | 1 |
| California | 1 |
| Illinois | 1 |
| New York | 1 |
| Pennsylvania | 1 |
| Tennessee | 1 |
| Texas | 1 |
Top cities
Self-screener
Recruiting trials
Related conditions
Trials recruiting for Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.